<?xml version='1.0' encoding='utf-8'?>
<document id="31758500"><sentence text="Mild polypharmacy and MCI progression in older adults: the mediation effect of drug-drug interactions." /><sentence text="Polypharmacy has been associated with worse cognitive performance, but its impact on mild cognitive impairment (MCI) progression to dementia has not been explored" /><sentence text="" /><sentence text="The aims of the study were to investigate the association between multidrug regimens and MCI progression, and the possible mediation of drug-drug interactions and drugs' anticholinergic effect in such association" /><sentence text="" /><sentence text="This work included 342 older adults with MCI, who were involved in an Italian multicenter population-based cohort study" /><sentence text=" Information on drugs taken was derived from general practitioners' records and data on drug-drug interactions and anticholinergic burden [evaluated through the Anticholinergic Cognitive Burden and the Anticholinergic Risk Scale (ARS)] were extracted" /><sentence text=" Multinomial logistic regressions assessed the associations between mild polypharmacy (≥ 3 drugs/day), drug-drug interactions, and anticholinergic burden with MCI changes after 1-year follow-up" /><sentence text=" Mediation analysis evaluated potential mediators of that relationship" /><sentence text="" /><sentence text="Approximately, 50% of participants took ≥ 3 drugs/day" /><sentence text=" During the follow-up, 4" /><sentence text="1% of MCI patients progressed to dementia" /><sentence text=" The odds of developing dementia was sixfold higher in those who took ≥ 3drugs/day (OR = 6" /><sentence text="04, 95% CI 1" /><sentence text="19-30" /><sentence text="74), eightfold higher in those with ≥ 1 drug-drug interaction/s (OR = 8" /><sentence text="45, 95% CI 1" /><sentence text="70-41" /><sentence text="91), and fivefold higher in those with ARS ≥ 1 (OR = 5" /><sentence text="10, 95% CI 1" /><sentence text="04-24" /><sentence text="93)" /><sentence text=" Drug-drug interactions mediated 70" /><sentence text="4% of the association between medication number and MCI progression to dementia (p = 0" /><sentence text="07)" /><sentence text="" /><sentence text="Our study suggests that even mild polypharmacy may increase the risk of MCI progression to dementia, probably due to the presence of drug-drug interactions, which often occur in multidrug regimens" /><sentence text="" /><sentence text="Older people require careful management of pharmacological treatments, with special attention to drug-drug interactions and drug-related anticholinergic effects" /><sentence text="" /></document>